Quick Answer
Nurix Therapeutics, Inc. reported Research And Development Expense of $316.90 million for the year ending 2025.
- Nurix Therapeutics, Inc. showed an increase of +43.0% in Research And Development Expense from 2024 to 2025.
- This data is from Nurix Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on January 28, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $11.01 million | Q1 2020: $12.97 million | Q2 2020: $14.14 million | Q3 2020: $18.94 million | Q1 2021: $23.00 million | Q2 2021: $25.99 million | Q3 2021: $30.91 million | Q1 2022: $43.14 million | Q2 2022: $47.49 million | Q3 2022: $47.76 million | Q1 2023: $45.82 million | Q2 2023: $45.76 million | Q3 2023: $47.86 million | Q1 2024: $50.01 million | Q2 2024: $48.92 million | Q3 2024: $55.48 million | Q1 2025: $69.66 million | Q2 2025: $78.10 million | Q3 2025: $86.12 million.
- Over the full 7 years of available data (2019 to 2025), Nurix Therapeutics, Inc.'s Research And Development Expense has grown by 603.8%.
- Historical annual values: Fiscal year 2025: $316.90 million | Fiscal year 2024: $221.63 million | Fiscal year 2023: $189.15 million | Fiscal year 2022: $184.50 million | Fiscal year 2021: $116.43 million | Fiscal year 2020: $66.49 million | Fiscal year 2019: $45.03 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: